Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib + Palbociclib in 11q13-amplified solid tumors
NCT06895733Phase 2Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib, palbociclib in solid tumor, urothelial carcinoma (UC), head and neck squamous cell carcinoma (HNSCC), sponsored by The Second Hospital of Tianjin Medical University. Started Nov 2024; status: recruiting.
02
Drugs
pazopanibpalbociclib
03
Conditions
solid tumorurothelial carcinoma (UC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06895733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895733.